Novartis AG announced a $2 billion acquisition of U.S. biotech Excellergy, a deal that will add the company’s lead anti‑IgE antibody Exl‑111 to Novartis’ allergy portfolio. The transaction, disclosed on March 27 2026, is structured with upfront and milestone payments that could total up to $2 billion and is expected to close in the second half of 2026.
The acquisition is part of Novartis’ strategy to offset the impact of patent cliffs on legacy products such as Entresto, Promacta and Tasigna. By adding a next‑generation anti‑IgE program, Novartis aims to sustain its 5‑6% sales compound annual growth rate target through 2030 and to complement its existing anti‑IgE therapy, Xolair, which generated $1.7 billion in sales in 2025 and received FDA approval for food allergies in February 2024.
Exl‑111 is a half‑life‑extended, high‑affinity anti‑IgE antibody that entered Phase 1 clinical trials in early February 2026 as part of the DISARM study. Early pharmacokinetic data suggest the antibody can achieve faster and deeper suppression of IgE signaling than current therapies, potentially improving symptom control for patients with food allergy, chronic spontaneous urticaria and allergic asthma.
Excellergy was founded in 2025 with $70 million in financing and its technology is built on research from Stanford University and the University of Bern. The company’s platform focuses on engineered cytokine‑receptor interactions (ECRIs) that enhance antibody potency and half‑life, positioning Exl‑111 as a differentiated product in a market that includes GSK’s recent $2.2 billion acquisition of RAPT Therapeutics for a similar anti‑IgE candidate.
Market reaction to the announcement was modest; Novartis shares dipped slightly in pre‑market trading, reflecting investor caution about the early‑stage nature of Exl‑111 and the competitive landscape. Nonetheless, analysts view the deal as a long‑term growth engine that could strengthen Novartis’ immunology pipeline and provide a new revenue stream to offset generic competition.
Management commentary underscored the strategic fit: “Excellergy adds a differentiated next‑generation anti‑IgE program that builds on biology Novartis knows well, supported by preclinical evidence and early clinical pharmacokinetic data,” said Fiona Marshall, President of Biomedical Research at Novartis. Todd Zavodnick, CEO of Excellergy, added, “This acquisition validates the transformative potential of our ECRIs and the hard work of the entire Excellergy team. Novartis brings world‑class global development capabilities and a proven track record of bringing novel medicines to patients.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.